{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:52:22Z","timestamp":1793242342486,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007914","name":"UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007914","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Ocular Surface"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jtos.2025.05.002","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T02:05:59Z","timestamp":1747015559000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Janus kinase inhibitors in the treatment of refractory cicatrizing conjunctivitis in pemphigoid"],"prefix":"10.1016","volume":"38","author":[{"given":"Celine","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebuka","family":"Eziama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo R.","family":"Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6129-9542","authenticated-orcid":false,"given":"Jennifer H.","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jtos.2025.05.002_bib1","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/archderm.138.3.370","article-title":"The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators","volume":"138","author":"Chan","year":"2002","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.jtos.2025.05.002_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103036","article-title":"Mucous membrane pemphigoid","volume":"21","author":"Du","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.jtos.2025.05.002_bib3","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.preteyeres.2004.05.005","article-title":"Ocular cicatricial pemphigoid: pathogenesis, diagnosis and treatment","volume":"23","author":"Ahmed","year":"2004","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.jtos.2025.05.002_bib4","first-page":"527","article-title":"Cicatricial pemphigoid","volume":"84","author":"Foster","year":"1986","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"5","key":"10.1016\/j.jtos.2025.05.002_bib5","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.4049\/jimmunol.165.5.2824","article-title":"The autoantibodies to \u03b16\u03b24 integrin of patients affected by ocular cicatricial pemphigoid recognize predominantly epitopes within the large cytoplasmic domain of human \u03b241","volume":"165","author":"Bhol","year":"2000","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.jtos.2025.05.002_bib6","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.clim.2004.04.010","article-title":"Profile of autoantibody to basement membrane zone proteins in patients with mucous membrane pemphigoid: long-term follow up and influence of therapy","volume":"112","author":"Yeh","year":"2004","journal-title":"Clin Immunol"},{"issue":"24","key":"10.1016\/j.jtos.2025.05.002_bib7","doi-asserted-by":"crossref","first-page":"11579","DOI":"10.1073\/pnas.88.24.11579","article-title":"Association of DQw7 (DQB1\u22170301) with ocular cicatricial pemphigoid","volume":"88","author":"Ahmed","year":"1991","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"10.1016\/j.jtos.2025.05.002_bib8","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1046\/j.1365-2133.2001.04380.x","article-title":"Mucous membrane pemphigoid: HLA-DQB1\u22170301 is associated with all clinical sites of involvement and may be linked to antibasement membrane IgG production","volume":"145","author":"Setterfield","year":"2001","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jtos.2025.05.002_bib9","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ophtha.2020.07.052","article-title":"Autoantibody detection for diagnosis in direct immunofluorescence-negative mucous membrane pemphigoid: ocular and other sites compared","volume":"128","author":"Dart","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2025.05.002_bib10","article-title":"Janus kinase inhibitors in autoimmune bullous diseases","volume":"14","author":"Huang","year":"2023","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.jtos.2025.05.002_bib11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s12026-020-09122-y","article-title":"Expression of JAK3, STAT2, STAT4, and STAT6 in pemphigus vulgaris","volume":"68","author":"Juczynska","year":"2020","journal-title":"Immunol Res"},{"issue":"13","key":"10.1016\/j.jtos.2025.05.002_bib12","doi-asserted-by":"crossref","first-page":"8112","DOI":"10.1167\/iovs.11-9322","article-title":"Profile of local interleukin expression in a cohort of ocular cicatricial pemphigoid patients","volume":"53","author":"Suelves","year":"2012","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.jtos.2025.05.002_bib13","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK\u2013STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.jtos.2025.05.002_bib14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ajoc.2018.12.001","article-title":"Tofacitinib for refractory uveitis and scleritis","volume":"13","author":"Paley","year":"2018","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.jtos.2025.05.002_bib15","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/2324400","article-title":"Role of Janus kinase (JAK) inhibitor in autoimmune ocular inflammation: a systematic review","volume":"2021","author":"Wen","year":"2021","journal-title":"J Immunol Res"},{"issue":"4","key":"10.1016\/j.jtos.2025.05.002_bib16","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ophtha.2018.01.014","article-title":"Evidence-based insights into the utility of conjunctival biopsy in mucous membrane pemphigoid","volume":"125","author":"Margolis","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2025.05.002_bib17","doi-asserted-by":"crossref","unstructured":"Eziama E, Nguyen C, Stephen Foster C, Heydinger S, Cao J. Novel grading scale for conjunctival inflammation in cicatrizing conjunctivitis associated with pemphigoid. Ocul Immunol Inflamm. doi:10.1080\/09273948.2024.2434128.","DOI":"10.1080\/09273948.2024.2434128"},{"issue":"1","key":"10.1016\/j.jtos.2025.05.002_bib18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jtos.2019.10.010","article-title":"Validation of a clinical assessment tool for cicatrising conjunctivitis","volume":"18","author":"Ong","year":"2020","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2025.05.002_bib19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jdcr.2022.07.013","article-title":"Successful treatment of recalcitrant mucous membrane pemphigoid with multisystem involvement with baricitinib and methotrexate","volume":"27","author":"Burningham","year":"2022","journal-title":"JAAD Case Rep"},{"issue":"4","key":"10.1016\/j.jtos.2025.05.002_bib20","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S0161-6420(82)34791-0","article-title":"Immunosuppressive therapy for progressive ocular cicatricial pemphigoid","volume":"89","author":"Foster","year":"1982","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.jtos.2025.05.002_bib21","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1111\/jdv.17397","article-title":"European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part I","volume":"35","author":"Rashid","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"10.1016\/j.jtos.2025.05.002_bib22","first-page":"1530","article-title":"S2k Guideline for the diagnosis and treatment of mucous membrane pemphigoid","volume":"20","author":"Hofmann","year":"2022","journal-title":"JDDG J der Deutschen Dermatol Gesellschaft"},{"issue":"2","key":"10.1016\/j.jtos.2025.05.002_bib23","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ophtha.2007.04.027","article-title":"Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes","volume":"115","author":"Saw","year":"2008","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.jtos.2025.05.002_bib24","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1097\/ICO.0000000000002080","article-title":"Clinical characteristics and outcomes of ocular cicatricial pemphigoid: a cohort study and literature review","volume":"38","author":"Fremont","year":"2019","journal-title":"Cornea"},{"issue":"5","key":"10.1016\/j.jtos.2025.05.002_bib25","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/ICO.0000000000003071","article-title":"A 10-year review of the management of ocular mucous membrane pemphigoid: a private practice experience","volume":"42","author":"Johnson","year":"2023","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2025.05.002_bib26","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13075-019-1964-1","article-title":"Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations","volume":"21","author":"McInnes","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"18","key":"10.1016\/j.jtos.2025.05.002_bib27","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s40265-017-0835-9","article-title":"Tofacitinib: a review in rheumatoid arthritis","volume":"77","author":"Dhillon","year":"2017","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.jtos.2025.05.002_bib28","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s40265-018-0908-4","article-title":"Baricitinib: a review in rheumatoid arthritis","volume":"78","author":"Al-Salama","year":"2018","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.jtos.2025.05.002_bib29","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1001\/jamaophthalmol.2018.3789","article-title":"Treatment of mucous membrane pemphigoid with Janus kinase inhibitor baricitinib","volume":"136","author":"Sarny","year":"2018","journal-title":"JAMA Ophthalmology"},{"key":"10.1016\/j.jtos.2025.05.002_bib30","article-title":"Tofacitinib for refractory ocular mucous membrane pemphigoid","volume":"22","author":"James","year":"2021","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"4","key":"10.1016\/j.jtos.2025.05.002_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajoint.2024.100078","article-title":"Mycophenolate mofetil for the treatment of cicatrizing conjunctivitis secondary to ocular pemphigoid","volume":"1","author":"Thompson","year":"2024","journal-title":"AJO International"},{"issue":"1","key":"10.1016\/j.jtos.2025.05.002_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajoint.2024.100087","article-title":"Rituximab and intravenous immunoglobulin in the treatment of cicatrizing conjunctivitis associated with pemphigoid","volume":"2","author":"Johnny","year":"2025","journal-title":"AJO International"},{"issue":"3","key":"10.1016\/j.jtos.2025.05.002_bib33","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jaad.2010.07.032","article-title":"Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients","volume":"65","author":"Kasperkiewicz","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jtos.2025.05.002_bib34","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","article-title":"A review on the safety of using JAK inhibitors in Dermatology: clinical and laboratory monitoring","volume":"13","author":"Samuel","year":"2023","journal-title":"Dermatol Ther"},{"issue":"11","key":"10.1016\/j.jtos.2025.05.002_bib35","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aat3834","article-title":"Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis","volume":"4","author":"Tvorogov","year":"2018","journal-title":"Sci Adv"},{"issue":"8","key":"10.1016\/j.jtos.2025.05.002_bib36","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1136\/annrheumdis-2016-210911","article-title":"JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment","volume":"76","author":"Zhang","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.jtos.2025.05.002_bib37","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1007\/s10067-020-04956-1","article-title":"Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis","volume":"39","author":"Kaine","year":"2020","journal-title":"Clin Rheumatol"}],"container-title":["The Ocular Surface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012425000631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012425000631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T09:54:43Z","timestamp":1764755683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542012425000631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":37,"alternative-id":["S1542012425000631"],"URL":"https:\/\/doi.org\/10.1016\/j.jtos.2025.05.002","relation":{},"ISSN":["1542-0124"],"issn-type":[{"value":"1542-0124","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Janus kinase inhibitors in the treatment of refractory cicatrizing conjunctivitis in pemphigoid","name":"articletitle","label":"Article Title"},{"value":"The Ocular Surface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtos.2025.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}